{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:29Z","timestamp":1761101249368},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,10,11]],"date-time":"2014-10-11T00:00:00Z","timestamp":1412985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12185-014-1684-x","type":"journal-article","created":{"date-parts":[[2014,10,10]],"date-time":"2014-10-10T08:10:01Z","timestamp":1412928601000},"page":"582-591","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms"],"prefix":"10.1007","volume":"100","author":[{"given":"Ludek","family":"Raida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Rusinakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romana","family":"Szotkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rohon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Skoumalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Divoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Pikalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Indrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Langova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,11]]},"reference":[{"issue":"5","key":"1684_CR1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","volume":"70","author":"PJ Tutschka","year":"1987","unstructured":"Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382\u20138.","journal-title":"Blood"},{"issue":"3","key":"1684_CR2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","volume":"7","author":"S Giralt","year":"2001","unstructured":"Giralt S, Thall PF, Khouri I, Wang X, Braunswchweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;7(3):631\u20137.","journal-title":"Blood"},{"issue":"5","key":"1684_CR3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1704166","volume":"32","author":"K Besien Van","year":"2003","unstructured":"Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003;32(5):471\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1684_CR4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bmt.1705271","volume":"37","author":"RK Dasgupta","year":"2006","unstructured":"Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poyton C, et al. Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant. 2006;37(5):455\u201361.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"1684_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1083-8791(03)00128-9","volume":"9","author":"DS Ritchie","year":"2003","unstructured":"Ritchie DS, Morton J, Szer J, Roberts AW, Durrant S, Shuttleworth P, et al. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2003;9(7):435\u201342.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"1684_CR6","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96(7):2419\u201325.","journal-title":"Blood"},{"issue":"5","key":"1684_CR7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","volume":"15","author":"K Besien Van","year":"2009","unstructured":"Van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, et al. Fludarabine-melphalan conditioning for aml and mds: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009;15(5):610\u20137.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"1684_CR8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5507\/bp.2011.040","volume":"155","author":"L Raida","year":"2011","unstructured":"Raida L, Tucek P, Faber E, Vondrakova J, Rusinakova Z, Skoumalova I, et al. Comparison of new FLU-BU12-TG conditioning with the standard BU-CY myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(4):327\u201332.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub."},{"issue":"Suppl 2","key":"1684_CR9","first-page":"S61","volume":"48","author":"M Mohty","year":"2013","unstructured":"Mohty M, Blaise D, Labopin M, Milpied N, Furst S, Tabrizi R, et al. Fludarabine, IV busulfan and antithymocyte globulins-based reduced-toxicity conditioning regimen (FB3) prior to allogeneic stem cell transplantation (allo-SCT): results of a multicentre prospective trial. Bone Marrow Transplant. 2013;48(Suppl 2):S61\u2013S61.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"1684_CR10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","volume":"21","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia. 2007;21(10):2109\u201316.","journal-title":"Leukemia"},{"issue":"8","key":"1684_CR11","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139.","journal-title":"Blood"},{"issue":"20","key":"1684_CR12","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","volume":"115","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, De Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer. 2009;115(20):4715\u201325.","journal-title":"Cancer"},{"issue":"5","key":"1684_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1703162","volume":"28","author":"F Nollet","year":"2001","unstructured":"Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant. 2001;28(5):511\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"1684_CR14","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute gvhd grading. Bone Marrow Transplant. 1995;15(6):825\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1684_CR15","first-page":"250","volume":"8","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;8(3):250\u20139.","journal-title":"Semin Hematol"},{"issue":"4","key":"1684_CR16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","volume":"13","author":"B Oran","year":"2007","unstructured":"Oran B, Giralt S, Saliva R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13(4):454\u201362.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"1684_CR17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bmt.2011.167","volume":"47","author":"RM Sobecks","year":"2012","unstructured":"Sobecks RM, Rybicki L, Yurch M, Kalaycio M, Dean R, Andresen S, et al. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone Marrow Transplant. 2012;47(5):633\u20138.","journal-title":"Bone Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1684-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1684-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1684-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T17:43:55Z","timestamp":1598377435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1684-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1684-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,11]]}}}